Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients.
作者信息
Xu Xiaoling, Han Mingfeng, Li Tiantian, Sun Wei, Wang Dongsheng, Fu Binqing, Zhou Yonggang, Zheng Xiaohu, Yang Yun, Li Xiuyong, Zhang Xiaohua, Pan Aijun, Wei Haiming
机构信息
Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui 230000, People's Republic of China;
Respiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang, Anhui 230000, People's Republic of China.
出版信息
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30898-30899. doi: 10.1073/pnas.2017204117. Epub 2020 Nov 17.
Abstract
摘要
相似文献
1
Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients.
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30898-30899. doi: 10.1073/pnas.2017204117. Epub 2020 Nov 17.
2
Tocilizumab in Covid-19. Reply.
N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.
3
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.
Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.
4
Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention.
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30027-30028. doi: 10.1073/pnas.2011616117. Epub 2020 Nov 12.
5
Tocilizumab in Covid-19.
N Engl J Med. 2021 Jan 7;384(1):86-87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.
6
Covid-19 controversies: the tocilizumab chapter.
BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.
7
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
8
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
Rheumatology (Oxford). 2021 Feb 1;60(2):977-979. doi: 10.1093/rheumatology/keaa653.
9
Tocilizumab for COVID-19: a real 'miracle drug'?
Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.
10
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
Ann Oncol. 2020 Jul;31(7):961-964. doi: 10.1016/j.annonc.2020.03.300. Epub 2020 Apr 2.
本文引用的文献
1
Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions?
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30896-30897. doi: 10.1073/pnas.2009961117. Epub 2020 Nov 17.
2
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
3
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm.
Nat Commun. 2020 Aug 6;11(1):3924. doi: 10.1038/s41467-020-17834-w.
4
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.
J Intern Med. 2021 Mar;289(3):434-436. doi: 10.1111/joim.13162. Epub 2020 Aug 18.
5
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Chest. 2020 Oct;158(4):1397-1408. doi: 10.1016/j.chest.2020.06.006. Epub 2020 Jun 15.
6
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
Eur J Intern Med. 2020 Jun;76:31-35. doi: 10.1016/j.ejim.2020.05.009. Epub 2020 May 13.
7
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
Med Mal Infect. 2020 Aug;50(5):397-400. doi: 10.1016/j.medmal.2020.05.001. Epub 2020 May 6.
8
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
9
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532. Epub 2020 May 1.
10
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
Zotero 插件